Precigen
PGEN
7.54
-0.01
-0.13%
Precigen
US · PGEN
#2527 by market cap
Listed 1970
7.54
-0.01
-0.13%
Live - 5344 symbols - heartbeat 52s ago
· 2026-10-08 07:00
Pre-market
7.50
-0.53%
After-hours
7.56
+0.27%
Overnight
7.50
-0.53%
- Market cap
- 2.70B
- P/E (TTM)i
- -7.05
- P/Bi
- 61.80
- EPSi
- -1.37
- Div yieldi
- 0.00%
- 52W posi
- 76%
Reader sentiment
Are you bullish or bearish on PGEN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -10.64, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +146.73% YoY
Margins
- Gross margin
- 50.20%
- Operating margin
- -1,100.78%
- Net margin
- -4,436.62%
Key ratios & quality
- Enterprise valuei
- 2.70B
- Altman Z-Scorei
- -10.64
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 151.18M | 31.99M | 103.18M | 14.27M | 26.91M | 6.23M | 3.93M | 9.68M |
| Gross profit | 88.50M | 26.62M | 47.67M | 8.52M | 20.57M | 106.00K | -342.00K | 4.86M |
| Selling & admin expenses | 125.16M | 72.69M | 91.70M | 51.99M | 48.01M | 40.42M | 41.29M | 70.13M |
| Research & development | 333.01M | 39.43M | 41.64M | 47.93M | 47.17M | 48.61M | 53.07M | 41.33M |
| Operating profit | -369.67M | -85.50M | -85.68M | -91.41M | -74.61M | -88.92M | -94.71M | -106.60M |
| Pretax profit | -395.91M | -104.52M | -103.86M | -110.97M | -79.97M | -96.36M | -128.03M | -250.64M |
| Tax | -15.43M | -82.00K | -82.00K | -160.00K | -189.00K | -458.00K | -1.79M | 3.00K |
| Net profit | -514.71M | -170.52M | -170.52M | -92.17M | 28.32M | -95.90M | -126.24M | -250.64M |
| Basic EPS | -4 | -1 | -1 | 0 | 0 | 0 | 0 | -1 |
| Diluted EPS | -3.93 | -1.02 | -1.02 | -0.47 | 0.14 | -0.39 | -0.47 | -1.37 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.34M | 856.00K | 2.92M | 4.57M | 23.25M | 54.98M |
| Gross profit | 241.00K | -236.00K | 1.89M | 2.97M | 20.69M | 52.17M |
| Selling & admin expenses | 12.36M | 16.13M | 23.99M | 17.65M | 21.05M | 22.25M |
| Research & development | 10.48M | 11.49M | 12.38M | 6.99M | 5.64M | 7.28M |
| Operating profit | -22.60M | -27.86M | -34.48M | -21.67M | -5.99M | 22.64M |
| Pretax profit | -54.15M | -26.64M | -146.34M | -23.50M | -7.93M | 20.07M |
| Tax | 0 | 3.00K | 0 | 0 | 0 | 0 |
| Net profit | -54.15M | -26.64M | -146.34M | -23.50M | -7.93M | 20.07M |
| Basic EPS | 0 | 0 | -1 | 0 | 0 | 0 |
| Diluted EPS | -0.18 | -0.09 | -1.06 | -0.01 | -0.02 | 0.05 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 285.48M | 234.64M | 148.95M | 156.63M | 118.16M | 68.76M | 102.41M | 115.24M |
| Cash & ST investments | 216.87M | 75.05M | 100.12M | 108.66M | 55.95M | 62.86M | 97.91M | 97.86M |
| Inventory | 20.58M | 16.10M | 11.36M | 326.00K | -- | -- | 0 | 9.58M |
| Total assets | 716.18M | 455.76M | 314.59M | 359.86M | 215.98M | 151.04M | 145.27M | 155.51M |
| Total current liabilities | 61.56M | 122.91M | 42.13M | 34.65M | 78.65M | 22.99M | 21.52M | 37.31M |
| Short-term debt | 945.00K | 36.23M | 3.02M | 1.45M | 44.43M | 1.20M | 956.00K | 1.14M |
| Long-term debt | 211.22M | 186.32M | 171.52M | 179.88M | -- | -- | -- | 93.17M |
| Total liabilities | 337,455,000.00 | 384,052,000.00 | 247,413,000.00 | 252,508,000.00 | 89,718,000.00 | 32,545,000.00 | 106,753,000.00 | 134,594,000.00 |
| Total equity | 378.72M | 71.71M | 67.17M | 107.35M | 126.26M | 118.50M | 38.51M | 20.91M |
| Retained earnings | -1.33B | -1.65B | -1.82B | -1.92B | -1.87B | -1.96B | -2.09B | -2.34B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 84.60M | 62.76M | 129.60M | 115.24M | 101.67M | 134.38M |
| Cash & ST investments | 80.24M | 59.75M | 121.14M | 97.86M | 56.25M | 38.21M |
| Inventory | -- | -- | 3.06M | 9.58M | 14.73M | 20.25M |
| Total assets | 128.79M | 101.90M | 171.26M | 155.51M | 138.63M | 170.30M |
| Total current liabilities | 23.99M | 23.19M | 32.07M | 37.31M | 21.10M | 29.35M |
| Short-term debt | 928.00K | 930.00K | 1.12M | 1.14M | 1.07M | 1.06M |
| Long-term debt | -- | -- | 92.89M | 93.17M | 93.52M | 93.88M |
| Total liabilities | 142,847,000.00 | 138,675,000.00 | 129,396,000.00 | 134,594,000.00 | 118,392,000.00 | 126,720,000.00 |
| Total equity | -14.06M | -36.78M | 41.87M | 20.91M | 20.24M | 43.58M |
| Retained earnings | -2.14B | -2.17B | -2.32B | -2.34B | -2.35B | -2.33B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -124.24M | -77.02M | -77.02M | -55.77M | -65.05M | -66.93M | -68.17M | -87.83M |
| Depreciation & amortization | 33.11M | 17.52M | 17.52M | 13.76M | 10.77M | 6.67M | 4.53M | 3.20M |
| Free cash flow | -165.83M | -84.55M | -84.55M | -63.02M | -69.97M | -68.47M | -76.76M | -89.83M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 87.99M | 35.00M | 35.00M | 121.05M | 0 | 72.81M | 31.24M | -1.66M |
| Ending cash balance | 110.18M | 52.25M | 52.25M | 43.34M | 48.60M | 7.85M | 29.52M | 30.23M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -16.33M | -18.98M | -29.07M | -23.46M | -43.83M | -17.81M |
| Depreciation & amortization | 629.00K | 630.00K | 803.00K | 1.14M | 1.10M | 1.10M |
| Free cash flow | -16.95M | -19.94M | -29.46M | -23.48M | -44.09M | -18.20M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -355.00K | 0 | -1.30M | 0 | 0 | 0 |
| Ending cash balance | 6.06M | 13.76M | 14.32M | 30.23M | 7.48M | 16.33M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -113.63 | -148.34 | -245.56 | -105.62 | 24.24 | -78.37 | -160.80 | -1,446.02 |
| ROA %i | -65.17 | -55.01 | -44.27 | -27.33 | 9.84 | -52.26 | -85.21 | -285.69 |
| ROIC %i | -93.01 | -68.98 | -54.32 | -27.19 | 14.58 | -65.06 | -150.49 | -525.67 |
| 5-year avg ROE %i | -40.44 | -51.78 | -97.76 | -112.94 | -103.81 | -96.76 | -113.22 | -353.31 |
| EBIT margin %i | -328.64 | -210.56 | -82.82 | -75.12 | -272.00 | -1,540.47 | -3,261.71 | -2,548.24 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.64 | 1.91 | 3.54 | 4.52 | 1.50 | 2.99 | 4.76 | 3.09 |
| Quick ratioi | 3.95 | 0.82 | 2.86 | 3.19 | 0.89 | 2.80 | 4.60 | 2.74 |
| Debt / assetsi | 29.62 | 51.05 | 57.94 | 52.82 | 23.81 | 4.70 | 3.79 | 63.21 |
| LT debt / equityi | 58.21 | 273.93 | 266.87 | 175.72 | 5.54 | 4.97 | 11.80 | 464.61 |
| Interest coveragei | -61.86 | -10.81 | -4.64 | -4.13 | -10.80 | -204.90 | -21,337.00 | -63.81 |
| Revenue CAGR (3Y) %i | -4.51 | -44.87 | -22.24 | -54.47 | -5.60 | -60.78 | -34.96 | -28.87 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -377.66 | -3,896.10 | -875.87 | -1,446.02 | -12,418.40 | -9,907.46 |
| ROA %i | -118.84 | -142.24 | -334.36 | -285.69 | -286.76 | -247.40 |
| ROIC %i | -333.09 | -1,415.72 | -424.80 | -525.67 | -693.98 | -597.72 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -3,770.75 | -2,870.25 | -3,899.94 | -2,548.24 | -625.55 | -172.64 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 3.53 | 2.71 | 4.04 | 3.09 | 4.82 | 4.58 |
| Quick ratioi | 3.39 | 2.60 | 3.81 | 2.74 | 3.93 | 3.76 |
| Debt / assetsi | 4.21 | 5.06 | 57.33 | 63.21 | 70.87 | 57.75 |
| LT debt / equityi | -- | -- | 231.85 | 464.61 | 480.27 | 223.27 |
| Interest coveragei | -31,681.80 | -41,523.00 | -272.48 | -63.81 | -29.18 | -15.21 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Papzimeos is the largest reported line at 96.53% of revenue, across 3 reported segments.
- The next-largest line, Service Revenues, is a distant second at 3.12% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Papzimeos96.53%
Service Revenues3.12%
Exemplar0.35%
Quote time 2026-10-08 07:00:08 · For reference only, not investment advice and not tailored to your situation.